SNGX - Soligenix announces $2.6M FDA grant to further study blood cancer candidate

• Clinical-stage biotech Soligenix, Inc. ( NASDAQ: SNGX ) announced Tuesday that the FDA had awarded a $2.6M grant to support studies for its experimental therapy HyBryte for expanded treatment in early-stage cutaneous T-Cell Lymphoma (CTCL).
• A photodynamic therapy, HyBryte, also known as SGX301, uses safe, visible light for activation. CRCL is a form of non-Hodgkin's lymphoma, a cancer involving white blood cells, which are essential for the body's immune function.
• The FDA's four-year Orphan Products Development grant was awarded to an academic institution that led the enrollment in the Phase 3 FLASH trial for the candidate in the treatment of early CTCL, SNGX said.
• The 50-patient trial for HyBryte will be conducted as an open-label study involving the highest enrolling clinical centers that took part in the FLASH study. The trial, named RW-HPN-MF-01, is expected to start in Q4 2022.

• Read more on data from the FLASH trial.

For further details see: